Ph+ALL
Conditions
Interventions
Case series:Oral flumatinib combined with chemotherapy
Sponsors
Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with relapsed and refractory Ph+ ALL, patients with first-line TKI intolerance and drug resistance; 2) Aged 14-70 years; 3) ECOG score 0-3; 4) Patients signing informed consent must be able to understand and willing to participate in this study, and sign informed consent at the same time.
Exclusion criteria
Exclusion criteria: 1) Exclude pregnant, preparing for pregnancy or lactating women; 2) Exclude patients with myelodysplastic syndrome (MDS), chronic myeloproliferative disease (MPN) and lymphoproliferative disease; 3) Exclude patients with severe liver and kidney and other important organ dysfunction or diseases affecting the treatment prognosis; 4) Exclude patients with other diseases that cannot be controlled and may limit patients' participation in this trial; 5) Exclude any circumstances that the investigator thinks are not suitable for the participants and that may increase the risk of the subjects or interfere with the test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR;MRD;Fusion gene quantification of BCR-ABL;OS;Disease-free survival, DFS;Concentration of flumatinib;safety; | — |
Countries
China
Contacts
Public ContactLi Hui
Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
Outcome results
None listed